ArticleFrontiers in neurology2024
Protective role of serum albumin in dementia: a prospective study from United Kingdom biobank.
Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Associations of Iron Indicators with Cognitive Impairment Risk in Postmenopausal Women: Evidence from a Matched Case-Control Study and Back Propagation Neural Network Model.Molecular neurobiology · 2026Article
- Article
- The relationship between cognitive function and inflammatory-nutritional status in schizophrenia: cognitive impairment is inversely related to PNI and CALLY indices.BMC psychiatry · 2026Article
- Association of the HALP score with baseline and incident physical-cognitive comorbidity and mortality: evidence from the WCHAT and UK Biobank cohorts.Frontiers in public health · 2026Article
- Multivariate associations between systemic inflammation, metabolic dysregulation, and cognitive performance in project FRONTIER.Frontiers in aging neuroscience · 2026Article
- Association between the Naples Prognostic Score and cognitive function in older adults: validation in Alzheimer's disease and vascular dementia.Frontiers in nutrition · 2026Article
- Association between red cell distribution width/serum albumin ratio and Parkinson's disease.European journal of medical research · 2025Article
- Interpretable machine learning for cognitive impairment prediction in Parkinson's disease: a multicenter validation study with SHAP analysis.Frontiers in aging neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A number of studies have explored the link between neurodegenerative disorders (NDDs) and albumin, the main protein in human plasma. However, the results have been inconsistent, highlighting the necessity for a detailed systemic analysis. Methods: Utilizing data from the United Kingdom Biobank, we investigated the relationship between baseline levels of serum and urine albumin and the occurrence of common NDDs, including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and dementia, employing Cox proportional hazards regression analysis. Results: Our results reveal that elevated baseline serum albumin levels are linked to a decreased risk of developing dementia (beta = -0.024, SE = 0.004, Conclusion: Our study underscores the potential role of serum albumin as a biomarker associated with reduced dementia risk. These findings contribute valuable insights into the understanding of albumin's impact on NDDs, suggesting its utility as a biomarker for dementia in clinical settings and informing future therapeutic strategies in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.